Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
Nakamoto keeps chief medical officer after reverse merger with KindlyMD
Nakamoto retained a Chief Medical Officer because it merged with healthcare provider KindlyMD and must maintain an operating healthcare arm to meet Nasdaq listing rules and avoid shell-company status. The legacy medical business supplies most of Nakamoto’s modest recurring revenue while the crypto treasury side faces scrutiny after a reported $238 million net loss, roughly $200 million in debt and heavy shareholder dilution from recent acquisitions. Management implemented a 1-for-40 reverse split to regain Nasdaq compliance; upcoming insider lock-up releases and the Q2 filing in August will test whether new revenues justify recent deals. » Altro su finance.yahoo.com
KindlyMD renames itself Nakamoto and pivots business toward Bitcoin
KindlyMD has officially changed its name to Nakamoto Inc. and is positioning itself going forward as a Bitcoin-focused company, while the healthcare business will continue under the subsidiary Kindly LLC. Shares and warrants will continue to trade on NASDAQ under the tickers NAKA and NAKAW. Nakamoto says it has built a Bitcoin reserve of more than $500 million and has invested in strategic international investments; the company plans to continue disciplined accumulation of its holdings and to build a portfolio of Bitcoin-native companies. » Altro su de.investing.com
KindlyMD announces share buyback program after massive price slump
KindlyMD approved a share buyback program for its outstanding common shares after the stock lost nearly 98% in six months and is trading close to its 52-week low. Management may make purchases in the market, in privately negotiated transactions and in block trades under Rule 10b-18; the program does not commit to acquiring a fixed number of shares. Despite the buyback plan, the company has high indebtedness and a very low short-term liquidity ratio of 0.13; at the same time KindlyMD secured a loan of USD 203 million to repay a convertible note and appointed new finance chiefs, while B. Riley issued a buy recommendation with a USD 2.00 price target. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 31,43M | 8.967,67% |
| Utile lordo | 18,17M | 5.241,81% |
| Utile netto | −116,53M | 5.590,36% |
| EBITDA | −99,15M | 4.855,53% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 58,39M€ |
Numero di azioni | 6,02M |
Massimo/minimo a 52 settimane | 29,83€ - 0,56€ |
| Dividendi | No |
Beta | -0,9 |
Rapporto P/E | −0,21 |
Rapporto PEG | 0,01 |
Rapporto P/B | 0,65 |
Rapporto P/S | 3,39 |
Profilo aziendale
| Nome | KINDLY MD INC. DL-,001 |
| CEO | Timothy Pickett |
| Dipendenti | 23 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | KDLY |
Scopri gli asset
Gli azionisti di KINDLY MD INC. DL-,001 investono anche nei seguenti asset
